Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells 5,230 Shares of Company Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew Posard sold 5,230 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the transaction, the director owned 53,609 shares in the company, valued at $5,818,720.86. This trade represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded up $2.92 during mid-day trading on Friday, reaching $109.86. The stock had a trading volume of 2,587,868 shares, compared to its average volume of 1,931,317. The firm has a 50 day moving average price of $102.94 and a two-hundred day moving average price of $81.25. The stock has a market capitalization of $12.47 billion, a P/E ratio of 32.79, a P/E/G ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $116.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Twin Capital Management Inc. increased its stake in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 161 shares in the last quarter. First Citizens Bank & Trust Co. lifted its position in shares of Halozyme Therapeutics by 2.0% in the first quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 175 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its position in shares of Halozyme Therapeutics by 1.2% in the first quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock valued at $981,000 after acquiring an additional 183 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Halozyme Therapeutics by 0.8% in the first quarter. Janney Montgomery Scott LLC now owns 25,373 shares of the biopharmaceutical company’s stock worth $1,640,000 after acquiring an additional 202 shares during the period. Finally, Tema ETFs LLC boosted its stake in shares of Halozyme Therapeutics by 0.6% in the second quarter. Tema ETFs LLC now owns 32,598 shares of the biopharmaceutical company’s stock worth $2,551,000 after acquiring an additional 210 shares during the period. Institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. TD Cowen increased their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.